novo nordisk glp-1 patent litigation The FDA has issued a warning to over its alleged failure to report adverse side effects, including death, in patients who took its medications, popularly known as Ozempic and GLP-1 Patent Landscape: Shifting Dimensions

The Bridge is a Centers for Medicare and Medicaid Services (CMS) demonstration that gives eligible Medicare Part D beneficiaries access to Wegovy, Foundayo, and the KwikPen formulation of Zepbound for a $50 per month medication copay, even if a prior Part D prior authorization for the same medication was declined

Most reported reactions overlap because both ultimately stimulate the same growth hormone release pathway

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial

1. Morning Vitamin C Booster Shot

Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States